Loading...

The current price of AKRO is 0 USD — it has increased 0.18 % in the last trading day.
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Wall Street analysts forecast AKRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKRO is 60.22 USD with a low forecast of 54.00 USD and a high forecast of 84.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Akero Therapeutics Inc revenue for the last quarter amounts to -90.24M USD, increased 10.44 % YoY.
Akero Therapeutics Inc. EPS for the last quarter amounts to -67171000.00 USD, decreased -4.62 % YoY.
Akero Therapeutics Inc (AKRO) has 63 emplpoyees as of December 16 2025.
Today AKRO has the market capitalization of 1.62B USD.